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Abstract: 
In this work, we have designed cyclic peptides (cIBL, cIBR, cIBC, CH4 and CH7) derived from the 
parent IB peptide (ICAM-11–21) that are inhibitors of ICAM-1/LFA-1-mediated T-cell adhesion to Caco-2 
cell monolayers. Cyclic peptide cIBR has the best activity of any of the peptides evaluated. The active 
ICAM-1 peptides have a common Pro-Arg-Gly sequence that may be important for binding to LFA-1. 
 
Graphic Abstract: 
Inhibition of LFA-1/ICAM-1-mediated Tcell adhesion by ICAM-1-derived peptides 
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Autoimmune diseases are characterized by the 
activation and migration of 'self'-reactive' T-cells 
to target antigens in a specific tissue or organ.1 
The process of T-cell migration from the blood 
stream to tissues involves the interaction 
between lymphocyte associated antigen-1 (LFA-
1) and intercellular adhesion molecule-1 
(ICAM-1).2 T-cell adhesion to vascular 
endothelial cells is mediated by the activated 
form of the LFA-1 integrin receptor. The 
activated form of LFA-1 can be induced in vivo 
by inflammatory cytokines and in vitro by anti 
CD-2 antibody or phorbol esters.3,4 This 
facilitates T-cell extravasation through vascular 
cell junctions into tissues containing the site of 
the autoimmune reaction and inflammation. 
 
Table 1. Sequences of ICAM-1-derived peptides. 
 
Name Amino Acid Sequence 
IB QTSVSPSKVILPRGGSVLVTG 
cIBL Cyclo(1,12)Pen-QTSVSPSKVICa 
cIBC Cyclo(1,12)Pen-PSKVILPRGGCa 
cIBR Cyclo(1,12)Pen-PRGGSVLVTGCa 
CH4 Cyclo(1,6)VILPRGb 
CH7 Cyclo(1,6)PRGGSVb 
CHK7 Cyclo(1,6)PRGGKVb 
aCyclic peptides were formed by disulfide bond from 
Pen1 to Cys12. bThese peptides were cyclized by an 
amide bond.  
 
Many therapies are currently being developed to 
treat the progression of autoimmune disease by 
modulating the interaction of LFA-1/ICAM-1. 
For example, anti-ICAM-1 and anti-CD11a 
monoclonal antibodies (mAb) have been shown 
to inhibit T-cell adhesion mediated by LFA-1 
and have been developed for the treatment of 
rheumatoid arthritis, insulin-dependent diabetes, 
and psoriasis.5,6 Also, small organic molecules 
such as lovastatin,7 p-arylthiocinnamides, and 
hydantoin derivatives (i.e., BRIT-377)8,9 have 
been shown to inhibit ICAM-1/LFA-1 inter-
actions by binding to the I-domain of LFA-1. 
 
In this work, we designed cyclic peptides that 
are derived from the parent linear peptide IB 
(ICAM-11–21) (Table 1). The sequence of the 
linear IB peptide was derived from ICAM-1, 
residues 1–21 of the Domain 1 (D1) N-terminus. 
The ability of peptides to inhibit ICAM-1/LFA-1 
interaction was evaluated using a heterotypic 
cell adhesion assay between a human leukemia 
T-cell line (Molt-3) and Caco-2 epithelial cell 
monolayers, which are a model for the intestinal 
mucosa.10,11 This experimental model of T-cell 
adhesion to intestinal mucosa is relevant to 
autoimmune diseases such as Crohn's disease 
and ulcerative colitis.2,12  
 
 
 
Figure 1. Concentration-dependent activity of 
ICAM-1 peptides in heterotypic T-cell adhesion 
assay. 
 
It is apparent that cIBR is the strongest inhibitor 
of T-cell adhesion at all concentrations (Figure 
1). At 500 µM cIBC is the second-most active 
peptide, followed by the cIBL and IB peptides, 
which are nearly equivalent. This result is 
consistent with previous findings in which the 
affinity of the cyclic peptides to the isolated 
LFA-1 receptor was also in the following order: 
cIBR>cIBC>cIBL.13 These results suggest that, 
for cIBR and cIBC, the conformational 
restriction induced by cyclization may contribute 
to their binding affinity to LFA-1 and ability to 
inhibit T-cell adhesion. Both cIBR and cIBC 
peptides contain β-turn-like structures around 
this PRG sequence as determined by NMR.14,15 
This sequence is representative of the β-hairpin 
turn that connects the A' and B β-strands in the 
D1 domain of ICAM-1.16 The negative control, 
VYPNGA, demonstrated no concentration-
dependent activity. The positive control RGD 
tripeptide demonstrated a concentration-
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dependent ability to inhibit T-cell adhesion, 
presumably by inhibiting other integrins. The 
cIBR peptide was a distinctly better inhibitor of 
T-cell adhesion than was the RGD control, 
suggesting that the ICAM-1/LFA-1 interaction is 
essential for the adhesion process. This indicates 
that LFA-1-mediated adhesion is the preferred 
mechanism utilized by T-cells to adhere to 
epithelial cells.  
 
The binding sites of cyclic peptides cIBL, cIBC, 
and cIBR were previously mapped to the I-
domain of LFA-1 and at a region partially 
overlapping with the binding site of anti-CD11a 
mAb R3.1 binding site.13 To demonstrate that 
ligand binding to this region of the I-domain of 
LFA-1 inhibits T-cell adhesion to Caco-2 
monolayers, the anti-LFA-1 antibody R3.1 was 
also used as a positive control (Figure 2). The 
R3.1 antibody inhibited the adhesion of T-cells 
to monolayers in a dose-dependent manner, 
suggesting that the ability of these peptides to 
inhibit T-cell adhesion was due to their binding 
to this region on the I-domain (Figure 2). 
 
 
 
Figure 2. Concentration-dependent inhibitory 
activity of LFA-1 mAb R3.1 in heterotypic T-cell 
adhesion assay. 
 
To evaluate the importance of the Pro-Arg-Gly 
sequence and to reduce the size of the cyclic 
peptide, we synthesized a series of linear 
hexapeptides LH1−LH8, which have over-
lapping sequences derived from the cIBC and 
cIBR peptides (Table 2). These peptides were 
evaluated at 200 µM for their ability to inhibit T-
cell adhesion (Table 2). Among these linear 
hexapeptides, LH4 (VILPRG) and LH7 
(PRGGSV) were found to be the most effective 
inhibitors of T-cell adhesion. Both peptides 
contain a Pro-Arg-Gly (PRG) sequence, also 
found in cyclic peptides cIBR and cIBC. These 
results suggest that the sequence and structure 
around this PRG motif are important for the 
activity of these peptides. 
 
Table 2. Linear hexapeptides derived from the 
sequences of cIBR and cIBC 
 
Name Sequence % T-cell 
Bindinga 
LH1 PSKVIL 44 ± 4 
LH2 SKVILP * 
LH3 KVILPR 49 ± 5 
LH4 VILPRG 32 ± 3 
LH5 ILPRGG 46 ± 4 
LH6 LPRGGS 37 ± 4 
LH7 PRGGSV 25 ± 1 
LHA1 AILPRG 53 ± 2 
LHA2 VALPRG 71 ± 2 
LHA3 VIAPRG 46 ± 2 
LHA4 VILARG 62 ± 1 
LHA5 VILPAG * 
LHA6 VILPRA 68 ± 2 
a Each peptide was used at a concentration of 200 µM 
in the cell adhesion assay. *This peptide was not 
evaluated due to its instability. 
 
The linear hexapeptide LH4 was subjected to 
alanine scanning to give linear hexapeptides 
LHA1−LHA6 (Table 2). Alanine substitution of 
Ile2, Pro4, or Gly6 residues reduced the activity 
of the peptide relative to LH4. This suggests that 
these residues play an essential role in the ability 
of these peptides to recognize LFA-1 and inhibit 
T-cell adhesion.  
 
To evaluate the effect of the conformation of 
peptides on inhibition of T-cell binding to Caco-
2 monolayers, cyclic hexapeptides CH4 and 
CH7, which were derived from the most 
effective linear hexapeptides LH4 and LH7, 
were synthesized (Table 1). The formation of 
cyclic hexapeptides has been shown to stabilize 
the β-turn structure and improve chemical and 
enzymatic stability. Therefore, the formation of 
CH4 and CH7 is expected to stabilize the β-turn 
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at their Pro-Arg-Gly sequence as in cIBC and 
cIBR peptides.15,14 Cyclic peptide CH7 has 
activity similar to that of the linear LH7 (Figure 
3). However, cyclic hexapeptide CH4 
demonstrated lower activity than its linear 
analog LH4. These results suggest that both 
conformational restriction and amino acid 
sequence influence the activity of these peptides. 
This difference in activity may be due to 
changes in the conformation of the backbone 
and the side chains of PRG sequence upon 
cyclization. In addition, cyclization may alter the 
ratio of cis to trans conformation at the Xaa-Pro 
peptide bond in CH4 and CH7, influencing their 
activity. 
 
 
 
Figure 3. Concentration-dependent activity of linear 
peptides LH4 and LH7, and cyclic peptides CH4 and 
CH7.  
 
 
Figure 4. Concentration-dependent activity of cyclic 
peptide CH7K compared to that of cyclic peptides 
cIBR, CH4 and CH7. 
 
This cyclic peptide CH7 may be developed as a 
targeted drug delivery system to LFA-1-
expressing T-cells.17 To accommodate drug 
conjugation, a Lys residue was incorporated by 
replacing Ser5 with Lys to give peptide CHK7 
(Table 1). Compared to CH7, the CHK7 peptide 
demonstrated lower activity, which suggests that 
the Ser5 residue is important for activity (Figure 
4). Figure 4 also shows that cIBR has the best 
inhibitory activity compared to the cyclic 
hexapeptides (CH4, CH7 and CHK7). In the 
future, other residues in CH7 will be substituted 
with Lys to find a derivative that maintains its 
LFA-1-binding activity. 
 
Figure 5. Molecular docking the cIBR peptide 
to the I-domain of LFA-1 at the metal ion-
dependent adhesion site (MIDAS). 
 
The binding sites of the cyclic and linear 
peptides on the I-domain of LFA-1 were 
evaluated using docking experiments.18,19 
Previously using monoclonal antibody inhibition 
assay, we have determined that these peptides 
bind to the I-domain of LFA-1.13 Docking 
studies of the cyclic peptides (cIBR, cIBC, and 
cIBL) reveal that these cyclic peptides have 
overlapping binding sites on the I-domain of 
LFA-1. Figure 5 shows that cIBR peptide binds 
at the groove region of the I-domain. Both of 
cIBR and cIBC peptides form hydrogen bonds to 
several residues on the I-domain, including 
Ala242, Asp244, Gln266, and Glu269. On the 
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other hand, cyclic peptide cIBL binds to the I-
domain around residues 143–149 close to the α4-
helix. The linear peptides LH4 and LH7 were 
predicted to bind to the I-domain between the α3-
β5 loop and α4-helix, which was similar to the 
binding site of cyclic peptide cIBL.  
 
Our results suggest that the active ICAM-1 
peptides have a common PRG sequence, which 
may be important for binding to LFA-1. 
Interestingly, another β2 integrin (αxβ2) was 
found to have a similar proline-containing 
recognition sequence, GPRP, which mediates 
rotavirus adhesion.20 Proline is known to 
stabilize β-turns. Here, Pro may stabilize the 
conformation of the linear peptides’ PRG motif, 
facilitating their recognition by the LFA-1 β2-
integrin. This has been demonstrated in RGD 
peptides with flanking proline residues, which 
help to maintain a favorable peptide 
conformation for recognition by β1- and β3-
integrins.21 
 
In conclusion, we have reduced a large ICAM-1 
peptide (IB) to a cyclic hexapeptide (CH7) that 
can bind to LFA-1 and inhibit T-cell adhesion in 
a concentration-dependent manner. The PRG 
motif may be important for the activity of these 
peptides. The cyclic peptide CH7 will be used to 
design peptidomimetics that can bind to the I-
domain of LFA-1. In addition, the cyclic 
hexapeptide CH7 will be optimized for targeting 
drugs to leukocytes. The studies presented here 
may ultimately lead to the identification of an 
optimal peptide for designing small 
peptidomimetics that retain the activity of these 
ICAM-1-derived peptides. 
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